| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
ASTRAZENECA PHARMA INDIA LTD. (BSE: 506820)
506820 Technical Analysis
5
| As on 5th Jul 2024 506820 SHARE Price closed @ 6891.75 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 5211.83 & Strong Buy for SHORT-TERM with Stoploss of 5916.75 we also expect STOCK to react on Following IMPORTANT LEVELS. |
506820SHARE Price
| Open | 7172.05 | Change | Price | % |
| High | 7172.05 | 1 Day | -228.40 | -3.21 |
| Low | 6851.10 | 1 Week | 651.75 | 10.44 |
| Close | 6891.75 | 1 Month | 888.30 | 14.80 |
| Volume | 2621 | 1 Year | 3161.05 | 84.73 |
| 52 Week High 7550.00 | 52 Week Low 3650.05 | ||||
BSE INDIA Most Active Stocks
| 512149 | 1.00 | -3.85% |
| 532648 | 26.63 | 11.14% |
| 532775 | 4.15 | 4.80% |
| 532822 | 17.09 | -2.40% |
| 530557 | 1.32 | -4.35% |
| 531752 | 1.76 | 19.73% |
| 509051 | 1.63 | -4.12% |
| 532154 | 1.20 | 4.35% |
| 531025 | 0.94 | -10.48% |
| 532411 | 0.41 | 0.00% |
BSE INDIA Top Gainers Stocks
BSE INDIA Top Losers Stocks
| 506820 Daily Charts |
506820 Intraday Charts |
Whats New @ Bazaartrend |
506820 Free Analysis |
|
|
506820 Important Levels Intraday
| RESISTANCE | 7510.22 |
| RESISTANCE | 7311.87 |
| RESISTANCE | 7189.27 |
| RESISTANCE | 7066.67 |
| SUPPORT | 6716.83 |
| SUPPORT | 6594.23 |
| SUPPORT | 6471.63 |
| SUPPORT | 6273.28 |
506820 Target November 2024
| 4th UP Target | 8811.49 |
| 3rd UP Target | 7986.8 |
| 2nd UP Target | 7477.04 |
| 1st UP Target | 6967.28 |
| 1st DOWN Target | 5512.72 |
| 2nd DOWN Target | 5002.96 |
| 3rd DOWN Target | 4493.2 |
| 4th DOWN Target | 3668.51 |
506820 Weekly Target
| 4th UP Target | 7376.45 |
| 3rd UP Target | 7011.98 |
| 2nd UP Target | 6786.70 |
| 1st UP Target | 6561.41 |
| 1st DOWN Target | 5918.59 |
| 2nd DOWN Target | 5693.30 |
| 3rd DOWN Target | 5468.02 |
| 4th DOWN Target | 5103.55 |
506820 Target2024
| 4th UP Target | 10603.3 |
| 3rd UP Target | 8972.99 |
| 2nd UP Target | 7965.28 |
| 1st UP Target | 6957.56 |
| 1st DOWN Target | 4082.14 |
| 2nd DOWN Target | 3074.42 |
| 3rd DOWN Target | 2066.71 |
| 4th DOWN Target | 436.42 |
ASTRAZENECA PHARMA INDIA LTD. ( BSE INDIA Symbol : 506820 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
506820 Business Profile
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and distributes pharmaceutical products in India and internationally. It manufactures and sells medicines under the Brilinta, Axcer, Forxiga, Oxra, Gledepa, Xigduo, Symbicort, Onglyza, Kombiglyze, Tagrisso, Lynparza, Zoladex, QTERN, and Imfinzi brand names. The company offers products in the areas of cardiovascular, renal, metabolic, oncology, antidiabetic, respiratory, inflammation, and autoimmunity diseases. It also provides clinical trial services. The company was founded in 1979 and is headquartered in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB. Address: Manyata Embassy Business Park, Bengaluru, India, 560045
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service